Eric S. Raymond

Learn More
Permission is granted to copy, distribute and/or modify this document under the terms of the Open Publication License, version 2.0. $Date: 2002/08/02 09:02:14 $ Revision History Revision 1.57 11 September 2000 esr New major section “How Many Eyeballs Tame Complexity”. Revision 1.52 28 August 2000 esr MATLAB is a reinforcing parallel to Emacs. Corbatoó &(More)
Reading is a hobby to open the knowledge windows. Besides, it can provide the inspiration and spirit to face this life. By this way, concomitant with the technology development, many companies serve the e-book or book in soft file. The system of this book of course will be much easier. No worry to forget bringing the the cathedral and the bazaar musings on(More)
BACKGROUND The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials. METHODS We conducted a multinational, randomized, double-blind, placebo-controlled phase 3 trial of sunitinib in patients with advanced, well-differentiated pancreatic neuroendocrine(More)
PURPOSE To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase inhibitor with antiangiogenic and antitumor properties, in patients with advanced malignancies. PATIENTS AND METHODS Sunitinib was given orally for 4 weeks every 6 weeks. RESULTS Twenty-eight patients received doses ranging(More)
Permission is granted to copy, distribute and/or modify this document under the terms of the Open Publication License, version 2.0. $Date: 2002/08/02 09:02:15 $ Revision History Revision 1.22 24 August 2000 esr Handicap theory, peacocks, and stags. Parallels with knighthood. Revision 1.22 24 August 2000 esr DocBook 4.1 conversion. Revision 1.21 31 Aug 1999(More)
PURPOSE To identify the optimal regimen and dosage of the oral mammalian target of rapamycin inhibitor everolimus (RAD001). METHODS We performed a dose-escalation study in advanced cancer patients administering oral everolimus 5 to 30 mg/wk, with pharmacokinetic (PK) and pharmacodynamic (PD) studies. PD data prompted investigation of 50 and 70 mg weekly(More)
Mammalian target of rapamycin (mTOR) is a kinase that functions as a master switch between catabolic and anabolic metabolism and as such is a target for the design of anticancer agents. The most established mTOR inhibitors--rapamycin and its derivatives--showed long-lasting objective tumour responses in clinical trials, with CCI-779 being a first-in-class(More)
EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies recommended for patients with this type of cancer. This is the first European joint effort by the European Association for the Study of the Liver (EASL) and the European Organization for(More)
PURPOSE To establish the safety and tolerability of ZD1839 (Iressa), a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and to explore its pharmacokinetic and pharmacodynamic effects in patients with selected solid tumor types. PATIENTS AND METHODS This was a phase I dose-escalating trial of oral ZD1839 150 mg/d to a maximum of(More)